Ardelyx faces class action over commercial performance disclosures

The litigation centers on claims that Ardelyx executives painted an overly optimistic picture of the company’s commercial strategy while concealing significant hurdles. According to the complaint, the firm failed to disclose intensifying payer-related access barriers, including stringent prior authorization and step edit requirements. These obstacles reportedly stifled new-patient starts and delayed prescription fulfillment, contradicting the company’s public assurances about its ability to meet revenue guidance.

The discrepancy surfaced on August 6, 2026, when Ardelyx slashed its full-year revenue forecast for IBSRELA and withdrew long-term growth projections for XPHOZAH. Management cited evolving market dynamics and increased utilization-management processes as the primary drivers behind the pivot. The market reaction was swift, with Ardelyx shares sliding from $4.87 to $4.00 within a single trading day, an 18% loss for investors.

Robbins LLP, the firm representing the class, notes that shareholders seeking to serve as lead plaintiff must contact the firm by November 16, 2026. Participation in the litigation carries no upfront cost, as the firm operates on a contingency fee basis. While the case seeks to recover losses stemming from what the complaint describes as artificially inflated stock prices, the firm emphasizes that individual investors are not required to act as lead plaintiffs to remain eligible for potential future recoveries.